DAX23.483 -0,4%Est505.726 -0,2%MSCI World4.343 -0,1%Top 10 Crypto9,9200 -0,7%Nas22.374 +1,2%Bitcoin64.331 -1,1%Euro1,1515 +0,1%Öl104,0 +3,0%Gold5.018 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Commerzbank CBK100 NVIDIA 918422 Siemens Energy ENER6Y BYD A0M4W9 Lufthansa 823212 Deutsche Telekom 555750 Bayer BAY001 SAP 716460 DroneShield A2DMAA Volkswagen (VW) vz. 766403 Allianz 840400 Deutsche Bank 514000 TUI TUAG50 Shell (ex Royal Dutch Shell) A3C99G
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX in Rot -- Asiens Börsen mehrheitlich im Minus -- Infineon, STMicro und NXP verkünden Kooperation mit NVIDIA -- Sartorius peilt überdurchschnittliches Wachstum an -- Rüstungsaktien im Fokus
Top News
Aktien von NVIDIA, Alphabet, Meta & Co. im Blick: Warum Bernstein jetzt das Ende der KI-Panik sieht Aktien von NVIDIA, Alphabet, Meta & Co. im Blick: Warum Bernstein jetzt das Ende der KI-Panik sieht
DAX 40-Papier Volkswagen (VW) vz-Aktie: So viel Verlust hätte ein Investment in Volkswagen (VW) vz von vor 5 Jahren eingebracht DAX 40-Papier Volkswagen (VW) vz-Aktie: So viel Verlust hätte ein Investment in Volkswagen (VW) vz von vor 5 Jahren eingebracht
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Renditechancen in Schwellenländern entdecken - mit ETFs von Amundi einfach und günstig investieren.
Wer­bung

Alvotech Registered Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
3,08 EUR -0,14 EUR -4,35 %
STU
3,63 USD +0,17 USD +4,76 %
BTT
finanzen.net zero
Alvotech Registered jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.938,93 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DK8U

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINLU2458332611

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolALVO

Alvotech Registered Aktien News

DatumMeistgelesen
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO
GlobeNewswireAlvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
GlobeNewswireAlvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
Wer­bungAlvotech Registered-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
GlobeNewswireAlvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
GlobeNewswireAlvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
GlobeNewswireAlvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia®
GlobeNewswireAlvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
GlobeNewswireAlvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
GlobeNewswireAlvotech Annual General Meeting to be held June 25, 2025
GlobeNewswireTransactions of Managers and Closely Associated Persons
GlobeNewswireAlvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
GlobeNewswireTrading in Alvotech’s Shares on Nasdaq Stockholm Commences Today
GlobeNewswireAlvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm
GlobeNewswireTransactions of Managers and Closely Associated Persons
GlobeNewswireTransactions of Managers and Closely Associated Persons
GlobeNewswireAlvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada  
GlobeNewswireTransactions of Managers and Closely Associated Persons
GlobeNewswireAlvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
GlobeNewswireAlvotech Reports Results for the First Quarter of 2025 and Provides Business Update
GlobeNewswirePotential U.S. Tariffs on Pharmaceuticals Expected to Have Minimal Impact on Alvotech’s Product Revenues in 2025
GlobeNewswireTeva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
GlobeNewswireAlvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
GlobeNewswireAlvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
GlobeNewswireAlvotech Reports Record Results for 2024 and Provides Business Update
GlobeNewswireUK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
GlobeNewswireAlvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
GlobeNewswireAlvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
GlobeNewswireAlvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
GlobeNewswireAlvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
GlobeNewswireTeva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
GlobeNewswireAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
GlobeNewswireAlvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
GlobeNewswireAlvotech Reports Financial Results for the First Nine Months of 2024
GlobeNewswireAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
GlobeNewswireEuropean Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)
GlobeNewswireAlvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
GlobeNewswireAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
GlobeNewswireAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (us

Alvotech Registered News

Alvotech Registered News: auf dieser Seite finden Sie alle Alvotech Registered News und Nachrichten zur Alvotech Registered Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alvotech Registered News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alvotech Registered News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.